- THE MAGAZINE
The components incorporate a wide range of biocompatible ceramics, including alumina and zirconia; bioactive coatings, such as hydroxyapatite; medical-grade alloys, such as titanium and vanadium-free titanium; and medical-grade ultra-high-molecular-weight polyethylene (UHMWPE).
Kyocera gained practical experience with U.S. regulatory processes through its preliminary marketing of biocompatible components here beginning in the 1980s. The company shifted its development efforts to Japan in the mid-1990s, where it has achieved a high level of clinical success. Building on these experiences, Kyocera believes the JMM components can support medical system manufacturers in their efforts to meet the regulatory requirements of the U.S. Food and Drug Administration.
“The JMM product line represents decades of development, trials and clinical use, with exceptional success rates among tens of thousands of patients throughout Japan,” said John Rigby, president of Kyocera Industrial Ceramics. “These proven components can be instrumental to medical implant system manufacturers in their process of gaining permission to market the next generation of orthopedic joint replacement systems in the U.S.”
Based in Osaka, JMM is a joint venture founded in 2004 by Kyocera Corp. and Kobe Steel, Ltd. to provide biocompatible components and systems for use in orthopedic joint replacement applications. The company is based on material synergies gained through Kyocera’s extensive development of biocompatible ceramics since 1973, and Kobe Steel’s development of medical-grade alloys since 1984.
For additional information, visit www.kyocera.com or www.jmmc.jp/en.